These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21663838)

  • 21. Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy.
    Palacios R; Merchante N; Macias J; González M; Castillo J; Ruiz J; Márquez M; Gómez-Mateos J; Pineda JA; Santos J
    Antivir Ther; 2006; 11(4):529-35. PubMed ID: 16856627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin Resistance and the cardiometabolic syndrome in HIV infection.
    Bevilacqua M; Dominguez LJ; Barbagallo M
    J Cardiometab Syndr; 2009; 4(1):40-3. PubMed ID: 19245515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy.
    Estrada V; Martínez-Larrad MT; González-Sánchez JL; de Villar NG; Zabena C; Fernández C; Serrano-Ríos M
    Metabolism; 2006 Jul; 55(7):940-5. PubMed ID: 16784968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART).
    Vigouroux C; Gharakhanian S; Salhi Y; Nguyen TH; Chevenne D; Capeau J; Rozenbaum W
    Diabetes Metab; 1999 Sep; 25(3):225-32. PubMed ID: 10499191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
    Falutz J
    Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proinflammatory markers, insulin sensitivity, and cardiometabolic risk factors in treated HIV infection.
    Samaras K; Gan SK; Peake PW; Carr A; Campbell LV
    Obesity (Silver Spring); 2009 Jan; 17(1):53-9. PubMed ID: 19008869
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiretroviral therapy with heart.
    Randell P; Moyle G
    Am J Ther; 2009; 16(6):579-84. PubMed ID: 19940610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin resistance, HIV infection, and anti-HIV therapies.
    Taiwo BO
    AIDS Read; 2005 Apr; 15(4):171-6, 179-80. PubMed ID: 15844237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV lipodystrophy and its metabolic consequences: implications for clinical practice.
    Wierzbicki AS; Purdon SD; Hardman TC; Kulasegaram R; Peters BS
    Curr Med Res Opin; 2008 Mar; 24(3):609-24. PubMed ID: 18208641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Disorders of lipid and glucose metabolism. Long-term adverse effects of antiretroviral therapy].
    Landauer N; Goebel FD
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():16-8. PubMed ID: 12043065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy.
    Senise JF; Castelo A; Martínez M
    AIDS Rev; 2011; 13(4):198-213. PubMed ID: 21975356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Diabetic ketoacidosis in an HIV-infected patient undergoing antiretroviral therapy].
    Holm MR; Hansen BR; Røder ME
    Ugeskr Laeger; 2006 Feb; 168(9):920-1. PubMed ID: 16513058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Coronary heart disease associated with the use of highly active antiretroviral therapy (HAART). A case report and review].
    Neumann T; Kondratieva J; Eggebrecht H; Wieneke H; Esser S; Bartel T; Erbel R
    Herz; 2005 Sep; 30(6):504-9. PubMed ID: 16170681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The future of antiretroviral therapy: challenges and needs.
    Moreno S; López Aldeguer J; Arribas JR; Domingo P; Iribarren JA; Ribera E; Rivero A; Pulido F;
    J Antimicrob Chemother; 2010 May; 65(5):827-35. PubMed ID: 20228080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endocrine and metabolic abnormalities among HIV-infected patients: a current review.
    Kibirige D; Ssekitoleko R
    Int J STD AIDS; 2013 Aug; 24(8):603-11. PubMed ID: 23970578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients.
    Srinivasa S; Grinspoon SK
    Eur J Endocrinol; 2014 May; 170(5):R185-202. PubMed ID: 24523497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of insulin resistance and risk of diabetes mellitus in HIV-infected patients receiving current antiretroviral drugs.
    Araujo S; Bañón S; Machuca I; Moreno A; Pérez-Elías MJ; Casado JL
    Eur J Endocrinol; 2014 Nov; 171(5):545-54. PubMed ID: 25117462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction.
    Shikuma CM; Day LJ; Gerschenson M
    Curr Drug Targets Infect Disord; 2005 Sep; 5(3):255-62. PubMed ID: 16181144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [HIV infection in France in 2012: reality, risks and challenges for a chronic multisystem disease].
    Blot M; Piroth L
    Rev Mal Respir; 2012 Jun; 29(6):785-92. PubMed ID: 22742465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucose disorders associated with HIV and its drug therapy.
    Hardy H; Esch LD; Morse GD
    Ann Pharmacother; 2001 Mar; 35(3):343-51. PubMed ID: 11261533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.